stypoldione: ortho-quinone from brown algae Stypopodium zonale; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 3034636 |
MeSH ID | M0118819 |
Synonym |
---|
stypoldione |
nsc339672 , |
71103-05-4 |
(1s,2s,4ar,4bs,7s,8ar,10ar)-7-hydroxy-2,4b,7',8,8,10a-hexamethyl-spiro[2,3,4,4a,5,6,7,8a,9,10-decahydrophenanthrene-1,2'-3h-benzofuran]-4',5'-dione |
spiro[benzofuran-2(3h),1'(2'h)-phenanthrene]-4,5-dione, 3',4',4'a,4'b,5',6',7',8',8'a,9',10',10'a-dodecahydro-7'-hydroxy-2',4'b,7,8',8',10'a-hexamethyl-, (2s,2's,4b's,7's,10a'r)- |
(1s,2s,4ar,4bs,7s,8ar,10ar)-7-hydroxy-2,4b,7',8,8,10a-hexamethylspiro[2,3,4,4a,5,6,7,8a,9,10-decahydrophenanthrene-1,2'-3h-1-benzofuran]-4',5'-dione |
16,24-cyclo-13,17-secochola-16,20(22)-diene-23,24-dione, 14,17-epoxy-3-hydroxy-4,4,8-trimethyl-, (3beta,5alpha,13alpha)- |
y7jz2j63q7 , |
unii-y7jz2j63q7 |
nsc 339672 |
XS177357 |
spiro[benzofuran-2(3h),1'(2'h)-phenanthrene]-4,5-dione, 3',4',4'a,4'b,5',6',7',8',8'a,9',10',10'a-dodecahydro-7'-hydroxy-2',4'b,7,8',8',10'a-hexamethyl-, (1's,2's,4'ar,4'bs,7's,8'ar,10'ar)- |
Stypoldione is a marine natural product that inhibits cells division in marine embryos and in mammalian cell cultures.
Excerpt | Reference | Relevance |
---|---|---|
"Stypoldione is a marine natural product that inhibits cells division in marine embryos and in mammalian cell cultures. " | ( Selective inhibition of cytokinesis in sea urchin embryos by low concentrations of stypoldione, a marine natural product that reacts with sulfhydryl groups. Asai, DJ; Jacobs, RS; O'Brien, ET; Wilson, L, 1989) | 1.94 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (50.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (12.50%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |